| Literature DB >> 23450738 |
Ermengol Coma1, Manel Ferran, Leonardo Méndez, Begoña Iglesias, Francesc Fina, Manuel Medina.
Abstract
INTRODUCTION: The development of electronic medical records has allowed the creation of new quality indicators in healthcare. Among them, synthetic indicators facilitate global interpretation of results and comparisons between professionals.Entities:
Keywords: Feedback; Health care quality indicators; Primary care
Year: 2013 PMID: 23450738 PMCID: PMC3581769 DOI: 10.1186/2193-1801-2-51
Source DB: PubMed Journal: Springerplus ISSN: 2193-1801
Structure and weighted scoring of the synthetic indicator “Healthcare Quality Standard 2007
| Clinical condition in adults | Relative weight | |
|---|---|---|
| Indicator | ||
| 1 | Diagnosis of new cases | 14 |
| 2 | Follow-up | 12 |
| 3 | Of individuals who are dependent on family members | 13 |
| 4 | Of frail elderly individuals | 16 |
| 5 | Antiplatelet/anticoagulant treatment | 30 |
| 6 | Lipid control | 26 |
| 7 | Beta-blockers treatment | 26 |
| 8 | Antiplatelet/anticoagulant treatment | 26 |
| 9 | Lipid control | 23 |
| 10 | Cardiovascular Risk (CVR) record of hypercholesterolemia | 30 |
| 11 | Antiplatelet/anticoagulant treatment | 38 |
| 12 | Blood pressure (BP) control | 44 |
| 13 | Blood pressure (BP) control in at-risk population (IHD, DM, CVD/TIA, Chronic Kidney Failure) | 25 |
| 14 | ACEI/ARB treatment | 26 |
| 15 | Beta-blockers treatment | 23 |
| 16 | Vaccination for hepatitis B virus | 23 |
| 17 | Screening for alcohol use | 26 |
| 18 | Screening for tobacco use in at-risk population | 26 |
| 19 | Smoking cessation | 29 |
| 20 | Screening and onset prevention | 20 |
| 21 | HbA1c control | 30 |
| 22 | Screening and prevention of diabetic retinopathy | 23 |
| 23 | ACEI/ARB treatment in DM2 with chronic nephropathy | 24 |
| 24 | Syndrome diagnosis, new cases of cognitive deterioration | 17 |
| 25 | Home health care interventions for a safe living environment for patients with dementia | 13 |
| 26 | Assessment of caregiver burnout | 16 |
| 27 | Removal of earwax plugs in primary care | 10 |
| 28 | Diagnosis of new cases of asthma | 22 |
| 29 | Flu shots in patients aged ≥60 years | 29 |
| 30 | Flu shots in at-risk patients | 20 |
| 31 | Pneumonia shots in patients aged ≥60 years | 5 |
| 32 | Tetanus shots | 35 |
| 33 | Diagnosis of new cases | 23 |
| 34 | Training in use of COPD inhalers | 12 |
| 35 | Case complexity assessment of patients with ATDOM | 16 |
| 36 | Assessment of pressure ulcers risk | 26 |
| 37 | Contact within 48 hours with PREALT patients | 12 |
| 38 | Proper treatment of nephritic colic | 10 |
| 39 | Avoid improper use of PSA | 11 |
| 40 | Screening for congenital metabolic diseases | 7 |
| 41 | Introduction of foods at recommended stages | 7 |
| 42 | Systematic infant vaccinations (0–14 years) | 10 |
| 43 | Control of growth and development (0–2 years) | 8 |
| 44 | Screening for passive smoking ≤2-year-olds | 7 |
| 45 | Maintenance of maternal lactation | 6 |
| 46 | Measles vaccination at 13 years | 6 |
| 47 | Dental cavity preventive treatment (6–12 years) | 7 |
| 48 | Screening for ocular diseases (0–6 years) | 8 |
| 49 | Flu shots in at-risk children <15 years | 7 |
| 50 | Screening for toxic habits (11–14 years) | 7 |
| 51 | Umbilical hernia in children ≤3 years | 5 |
| 52 | Contagious mollusk and viral warts (0–14 years ) | 6 |
| 53 | Neonatal dacryocystitis <9 months | 6 |
| 54 | Treatment of acute gastroenteritis (3 months to 14 years ) | 7 |
| 55 | Treatment of tonsillitis, pharyngitis or pharyngotonsillitis <3 years | 7 |
| 56 | Treatment of acute bronchiolitis <2 years | 6 |
| 57 | Treatment of catarrh in upper respiratory infection or flu <15 years | 7 |
| 58 | Treatment of acute nonsuppurative otitis media (2–14 years ) | 7 |
| 59 | Diagnosis of childhood asthma (7 a 14 years ) | 8 |
| 60 | Calculation of body mass index in obesity or weight gain (6–14 years ) | 7 |
| 61 | Social assessment of children with a disability (<15 years) | 4 |
| Total | 1000 | |
Figure 1Number of healthcare professionals who consult their EQA quality outcomes.
Figure 2Examples of subindicators, with numbers of patients diagnosed and managed.
Difference (%) of resolved cases between 2007 and 2010 by subindicator
| INDICATOR | January 2007 | December 2010 | Difference | % Difference |
|---|---|---|---|---|
| Treatment with beta- blockers | 44,484 | 66,338 | 21,854 | 49.13 |
| Treatment with antiplatelets | 82,120 | 103,482 | 21,362 | 26.01 |
| Control of lipids | 24,269 | 60,105 | 35,836 | 147.66 |
| Treatment with ACEI or ARB | 25,705 | 34,342 | 8,637 | 33.60 |
| Treatment with beta- blockers | 9,738 | 21,073 | 11,335 | 116.40 |
| Treatment with antiplatelets | 48,851 | 67,265 | 18,414 | 37.69 |
| Control of lipids | 10,127 | 33,498 | 23,371 | 230.78 |
| 563,524 | 684,125 | 120,601 | 21.40 |
Figure 3a. Evolution of EQA subindicatorsby PCT greater areas. Resolved rates by 1000 inhabitants (h). January 2007 - January 2011. b. Evolution of EQA subindicators (22 to 39) by PCT greater areas. Resolved rates by 1000 inhabitants (h). January 2007 - January 2011.